Exclusive Summary

• Clear Market Entry Window: The originator's patent has expired in most regions globally, offering low barriers for generic entry, with significant opportunities in emerging markets.
• Unique Clinical Value: As a second-generation antihistamine with a dual mechanism of action (antagonist of both histamine H1 and Platelet-Activating Factor receptors), it offers superior symptom control for allergic rhinitis and urticaria compared to some traditional agents, providing a clear differentiation point.
• Massive Patient Base & Guideline Recommendation: Allergic diseases affect 10-30% of the global population. Rupatadine is recommended as a first-line treatment in multiple international guidelines, addressing a huge and stable market demand.
• Internationally Recognized Quality Standard: The product is PIC/S GMP certified, meaning its quality management system meets the stringent standards of over 50 countries/regions, including the EU, Canada, and Australia, which can greatly simplify the registration process for partners and build market trust.